Definitions of Sexual Dysfunctions in Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015
McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Lewis R, +1 more
Journal of Sexual Medicine (2016)
The Fourth ICSM consensus reconciliation of DSM-5, ICD-10, and society-specific definitions for sexual dysfunctions — the framework reference for HSDD, FSIAD, female orgasmic disorder, and genito-pelvic pain/penetration disorder against which contemporary trials are designed and contemporary pharmacology is labeled.
This is the Fourth International Consultation on Sexual Medicine (ICSM 2015) consensus statement on the definitions of sexual dysfunctions in women and men — the reference document that reconciles the partly-overlapping diagnostic frameworks of the DSM-5, the ICD-10, the International Society for Sexual Medicine, and several specialty-society standards into a single set of evidence-based working definitions used by contemporary sexual-medicine practice and by the FDA-approved indication labels for the small handful of FSD-class pharmaceuticals. The authors — representing nine international experts in sexual medicine, psychiatry, urology, gynecology, and behavioral psychology — conducted a systematic review of the existing definitional landscape, evaluated evidence-based revisions against epidemiologic and outcome-trial data, and produced a coherent reference framework.
The principal contributions of the consensus include: (1) reconciliation of the DSM-5 framework's collapse of hypoactive sexual desire disorder and female sexual arousal disorder into a unified female sexual interest/arousal disorder (FSIAD) with the legacy four-domain framework that the regulatory and trial literature continued to use (preserving separate definitions of HSDD and FSAD for clinical and research use); (2) operational definitions for delayed ejaculation, erectile dysfunction, female orgasmic disorder, female sexual interest/arousal disorder, premature (early) ejaculation, and male hypoactive sexual desire disorder; (3) definition of genito-pelvic pain/penetration disorder consistent with DSM-5 framing and integration of vaginismus, dyspareunia, and vestibulodynia within a unified diagnostic structure; (4) explicit duration and distress criteria for each diagnosis (≥6 months of symptoms, clinically significant distress, exclusion of substance-, medication-, or general-medical-condition-attributable cases). The companion paper in the same J Sex Med issue (McCabe et al. 2016, 13:144–152) addresses prevalence and incidence across the resulting diagnoses; subsequent ICSM iterations have refined specific definitions but the 2016 statement remains the reference reconciliation.
The clinical and regulatory relevance is substantial. The PT-141 / bremelanotide RECONNECT trials used ICSM-aligned HSDD criteria for primary endpoint definition (sexual desire and distress measures). The Clayton et al. 2018 ISSWSH Process of Care for HSDD operationalizes the HSDD-specific framework into clinical workflow. The female sexual dysfunction beyond Vyleesi dossier walks the contemporary regulatory and off-label landscape against the ICSM 2016 definitional framework. Trials designed to DSM-5 FSIAD endpoints versus ICSM HSDD endpoints test partially overlapping but not identical conditions, and the cross-trial comparison literature has had to navigate this definitional plurality continuously since 2013.
This is an expert consensus reconciliation rather than a primary research paper; the evidentiary base for each definition is the underlying epidemiologic, clinical, and trial literature the authors synthesize rather than a single new dataset. The consensus is partly descriptive (codifying what the literature uses) and partly prescriptive (recommending revisions to clarify or update definitions); both modes are present and not always cleanly separable. The DSM-5 versus ICSM-versus-ISSWSH divergence on HSDD/FSAD versus FSIAD has not been resolved at the field level — both diagnostic frameworks continue to be used in research, clinical, and regulatory contexts, complicating cross-trial comparison and producing the structural confusion described in the female sexual dysfunction beyond Vyleesi dossier. The authorship is predominantly senior North American and European sexual-medicine specialists; cross-cultural and lower-middle-income-country applicability is partly addressed in the prevalence companion paper but is not the primary focus of this definitional statement. Industry support and individual disclosures are reported in the supplemental material. The framework has been replicated and refined in subsequent ICSM iterations and is incorporated into the AUA, EAU, and ACOG guidance for contemporary FSD diagnosis. The PT-141 peptide page anchors the bremelanotide-specific clinical pharmacology that operates within this diagnostic framework.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.